Natus Medical Inc

Find Ratings Reports
BABY : NASDAQ : Health Care
$38.1 -0.6 | -1.55%
Today's Range: 38.0 - 39.0
Avg. Daily Volume: 429700.0
03/29/17 - 4:00 PM ET

Financial Analysis


NATUS MEDICAL INC's gross profit margin for the fourth quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. NATUS MEDICAL INC is extremely liquid. Currently, the Quick Ratio is 4.18 which clearly shows the ability to cover any short-term cash needs. BABY managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

During the same period, stockholders' equity ("net worth") has increased by 6.82% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)107.799.95
EBITDA ($mil)23.5921.3
EBIT ($mil)19.5316.66
Net Income ($mil)10.238.54


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)247.5782.47
Total Assets ($mil)649.01479.5
Total Debt ($mil)140.00.0
Equity ($mil)417.37390.71


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin62.5665.5
EBITDA Margin21.921.31
Operating Margin18.1316.67
Sales Turnover0.590.78
Return on Assets6.567.9
Return on Equity10.29.7
Debt Q4 FY16 Q4 FY15
Current Ratio5.083.13
Debt/Capital0.250.0
Interest Expense0.080.35
Interest Coverage247.247.34


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)32.9233.15
Div / share0.00.0
EPS0.310.26
Book value / share12.6811.78
Institutional Own % n/a n/a
Avg Daily Volume421850.0443334.0

Valuation


BUY. This stock's P/E ratio indicates a significant discount compared to an average of 45.60 for the Health Care Equipment & Supplies industry and a premium compared to the S&P 500 average of 26.28. To use another comparison, its price-to-book ratio of 3.04 indicates valuation on par with the S&P 500 average of 2.93 and a significant discount versus the industry average of 4.70. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, NATUS MEDICAL INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BABY 29.92 Peers 45.60   BABY 17.48 Peers 25.76

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

BABY is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

BABY is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BABY 17.59 Peers 31.47   BABY 0.75 Peers 1.14

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

BABY is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

BABY trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BABY 3.04 Peers 4.70   BABY 12.17 Peers 98.63

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

BABY is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, BABY is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BABY 3.33 Peers 4.76   BABY 1.60 Peers 13.66

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BABY is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BABY significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades